L3VLUP
ProSign in

ABOS in the 13F filings

Acumen Pharmaceuticals Inc · CUSIP 00509G209

Sector · Pharmaceuticals and biotechnologyTheme · Biological productsTheme · Healthcare: biopharma and medtech· L3VLUP-defined
Quarter
Q1 2024Q4 2023Q3 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021
Quarter end
30 Sep 2021
the date the book describes
Filed
15 Nov 2021
latest of these filings; the earliest 15 Nov 2021
Managers listing it
2
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q2 2021 and Q3 2021; 0 listed it in both
Shares listed
838,377
combined, among listed positions
Reported value
$12m
combined, at the quarter end

Managers listing ABOS in Q3 2021

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q2 2021, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

2 of 2 holders

ActionFiling
Woodline Partners LP468,794$7.0m0.11%Newnew15 Nov 2021 (the filing on sec.gov)
Moore Capital Management LP369,583$5.5m0.08%Newnew15 Nov 2021 (the filing on sec.gov)

Largest increases and reductions, by shares

There is no earlier quarter on file to compare with.

Increases

Reductions

No reduction among listed positions.

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (2)

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
2 in Q1 2022 to 1 in Q1 2024

Tracked managers listing it, at least.

01122Q3 2021Q4 2021Q1 2022Q2 2022Q3 2022Q4 2022Q1 2023Q3 2023Q4 2023Q1 2024
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
ABOS by quarter
QuarterHoldersReported valueBuyersSellers
Q3 20212$12mn.a.n.a.
Q4 20212$5.7mn.a.n.a.
Q1 20222$3.4mn.a.n.a.
Q2 20222$3.7mn.a.n.a.
Q3 20222$8.6mn.a.n.a.
Q4 20222$2.5mn.a.n.a.
Q1 20231$1.7mn.a.n.a.
Q3 20231$2.2mn.a.n.a.
Q4 20231$2.2m10
Q1 20241$2.3m01

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

ABOS and GILD →ABOS and AMGN →ABOS and ARGX →Choose a stock to compare with ABOS →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own ABOS, latest filings →Back to the 13F Explorer →